🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: MF59C.1 Adjuvant

Found 11 matching trials

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

PHASE1

This research will study safety and the body's immune (defense system) resp...

Status

Completed

Location

Emory Children's Center - Pediatric Infectious Diseases

Start Date

2010-06

Trial ID

NCT00912496

Treatments Being Tested

MF-59 A/Anhui/05 Placebo

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

PHASE2

The present study is designed to confirm the safety and immunogenicity of t...

Status

Completed

Location

Antwerp University Centre for the Evaluation of Vaccination

Start Date

2013-07

Trial ID

NCT01879540

Treatments Being Tested

aTIV

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong

PHASE4

This study allows to evaluate the strength and duration of immune responses...

Status

Completed

Location

The University of Hong Kong

Start Date

2017-10-07

Trial ID

NCT03330132

Treatments Being Tested

Standard inactivated influenza vaccine (NH formulation)MF 59 adjuvanted inactivated influenza vaccine (NH formulation)High-dose inactivated influenza vaccine (NH formulation)Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

PHASE3

The present phase III study aims to evaluate the safety and immunogenicity ...

Status

Completed

Location

301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A

Start Date

2010-08

Trial ID

NCT01162122

Treatments Being Tested

MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)Non-adjuvanted trivalent subunit influenza vaccine (TIV)

Influenza Vaccination Strategy for Patients With Hematologic Malignancy

PHASE3

This randomized controlled trial evaluates and compares the immunogenicity ...

Status

Recruiting

Location

Asan Medical Center

Start Date

2025-12-04

Trial ID

NCT07485855

Treatments Being Tested

High-dose trivalent inactivated influenza vaccine (HD-IIV3)MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4)Standard-dose trivalent inactivated influenza vaccine (SD-IIV3)

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects

PHASE2

The present study will evaluate the immunogenicity, safety and tolerability...

Status

Completed

Location

Pestlőrinc-Pestszentimre Egészségügyi Szolgáltató KFT

Start Date

2008-12

Trial ID

NCT00841646

Treatments Being Tested

Monovalent inactivated influenza vaccine

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

PHASE1

This is an extension of the HVTN 073/SAAVI 102 study. This study will evalu...

Status

Completed

Location

Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

Start Date

2011-08

Trial ID

NCT01423825

Treatments Being Tested

Sub C gp140 Vaccine MF59C.1 Adjuvant Sodium chloride

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

PHASE1

The purpose of this study is to evaluate the safety and immune response to ...

Status

Completed

Location

Alabama CRS

Start Date

2011-07

Trial ID

NCT01376726

Treatments Being Tested

Sub C gp140 Vaccine MF59C.1 Adjuvant

Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza

N/A

As recommended by the Dutch Health Council, certain risk groups and health ...

Status

Completed

Location

Leiden University Medical Centre

Start Date

2009-11

Trial ID

NCT01066169

Treatments Being Tested

Foceteria® (Novartis)

Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

PHASE2

The present study aims to evaluate safety and immunogenicity of two doses, ...

Status

Completed

Location

Presidio Distrettuale N. 8, Azienda USL 7 di Siena, Via Savina Petrilli, 3

Start Date

2006-11

Trial ID

NCT00382187

Treatments Being Tested

MF59 adjuvanted H5N1 influenza vaccine

Previous Next